Differential clinical benefits of continuous blood purification treatment in critically ill patients with variable APACHE II scores

  • Authors:
    • Rui‑Xiang Zhou
    • Wei Dai
    • Chao‑Liang Hu
  • View Affiliations

  • Published online on: May 28, 2019     https://doi.org/10.3892/etm.2019.7617
  • Pages: 741-746
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to assess whether the Acute Physiology And Chronic Health Evaluation (APACHE) II score may be used to predict whether critically ill patients benefit from continuous blood purification (CBP) treatment. A total of 115 critically ill patients were retrospectively reviewed and grouped according to their baseline APACHE II scores. Each group was further divided into 2 groups based on whether they received CBP or not. At 72 h after CBP treatment, clinical indicators comprising the plasma levels of inflammatory cytokines, including tumor necrosis factor (TNF)‑α, interleukin (IL)‑6 and IL‑8, as well as endotoxin and procalcitonin (PCT), and severity scores (APACHE II, multiple organ dysfunction syndrome and systemic inflammatory response syndrome), were analyzed in all patients. It was observed that while CBP slightly reduced the severity scores in all patients, it significantly improved those in patients with an APACHE II score of 20‑29 (P<0.05). Similarly, the plasma levels of TNF‑α, IL‑6, IL‑8, endotoxin and PCT were significantly lower in patients receiving CBP than in those without CBP when the APACHE II score was 20‑29 (P<0.05). Furthermore, CBP treatment significantly decreased the fatality rate and length of stay at the intensive care unit (ICU) for critically ill patients with an APACHE II score of 20‑29 (P<0.05). In conclusion, CBP significantly decreases the inflammatory response, shortens the length of stay at the ICU and improves the prognosis for critically ill patients with an APACHE II score of 20‑29 points. This observation suggests that the APACHE II score is an important clinical indicator to determine the potential benefit of CBP therapy in critically ill patients.
View Figures
View References

Related Articles

Journal Cover

July-2019
Volume 18 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou RX, Dai W and Hu CL: Differential clinical benefits of continuous blood purification treatment in critically ill patients with variable APACHE II scores. Exp Ther Med 18: 741-746, 2019
APA
Zhou, R., Dai, W., & Hu, C. (2019). Differential clinical benefits of continuous blood purification treatment in critically ill patients with variable APACHE II scores. Experimental and Therapeutic Medicine, 18, 741-746. https://doi.org/10.3892/etm.2019.7617
MLA
Zhou, R., Dai, W., Hu, C."Differential clinical benefits of continuous blood purification treatment in critically ill patients with variable APACHE II scores". Experimental and Therapeutic Medicine 18.1 (2019): 741-746.
Chicago
Zhou, R., Dai, W., Hu, C."Differential clinical benefits of continuous blood purification treatment in critically ill patients with variable APACHE II scores". Experimental and Therapeutic Medicine 18, no. 1 (2019): 741-746. https://doi.org/10.3892/etm.2019.7617